ArQule, Inc. (NASDAQ:ARQL) is set to announce its earnings results before the market opens on Monday, November 6th. Analysts expect the company to announce earnings of ($0.11) per share for the quarter.

ArQule (NASDAQ:ARQL) last released its quarterly earnings data on Friday, August 4th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.01. During the same quarter in the previous year, the firm earned ($0.07) EPS. On average, analysts expect ArQule to post $-0.44 EPS for the current fiscal year and $-0.4 EPS for the next fiscal year.

Shares of ArQule, Inc. (NASDAQ:ARQL) opened at 1.04 on Monday. The stock’s 50 day moving average is $1.11 and its 200 day moving average is $1.12. ArQule, Inc. has a 52-week low of $0.92 and a 52-week high of $1.68. The stock’s market capitalization is $74.02 million.

A number of research analysts have commented on ARQL shares. Zacks Investment Research downgraded shares of ArQule from a “buy” rating to a “hold” rating in a research note on Wednesday, September 27th. ValuEngine downgraded shares of ArQule from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st.

A hedge fund recently raised its stake in ArQule stock. Northern Trust Corp raised its stake in shares of ArQule, Inc. (NASDAQ:ARQL) by 0.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 154,513 shares of the biotechnology company’s stock after acquiring an additional 1,385 shares during the quarter. Northern Trust Corp owned approximately 0.22% of ArQule worth $192,000 at the end of the most recent quarter. 61.01% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at

About ArQule

ArQule, Inc is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations.

Earnings History for ArQule (NASDAQ:ARQL)

Receive News & Ratings for ArQule Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule Inc. and related companies with's FREE daily email newsletter.